September 2003 Cover
|
 |
Gilead Sciences received approval from the US Food and Drug Administration last month for a new once-a-day AIDS drug, Emtriva. Known generically as
emtricitabine, Emtriva is a nucleoside reverse transcriptase inhibitor. Gilead now hopes to combine Emtriva with its other HIV drug, Viread, which is also taken once a day.
The company is planning a clinical trial to test such a combination pill against Combivir, rival drug maker Glaxo's once-a-day pill combining lamivudine and
AZT. But even as two separate pills, said Gilead CFO John Milligan, Viread and Emtriva could compete immediately against Combivir. Gilead said the wholesale price
of Emtriva would be $250 a month.
Editor's Note: from the New York Times
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
